Experiences with

Lymphocytic leukemia

Limited-duration combination therapies are starting to reshape how chronic lymphocytic leukemia (CLL) will be treated, but which combination is best is still unclear. https://cllsociety.org/2024/12/acalabrutinib-and-obinutuzumab-for-frontline-cll-treatment/

https://www.patientpower.info/chronic-lymphocytic-leukemia/reframing-cll-a-clinical-trial-journey-down-under

The association of MRD status as a surrogate end point of clinical outcome in chronic lymphocytic leukemia (CLL) has not been established in the era of targeted agents.

Richter transformation involves the evolution of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) into an aggressive lymphoma, Tedeschi and colleagues noted in their introduction.

[/i] * * * [u]Year in Review: Chronic Leukemia — Top news in 2024 included the first CAR-T approval for CLL, triplet regimens, and more[/u], by Ian Ingram, Managing Editor, MedPage Today December 10, 2024, Last Updated December 11, 2024 Developments in chronic lymphocytic

Below are the notes: There is mild leukocytosis with lymphocytosis The lymphocytes comprise of predominantly small mature forms and a subpopulation with clumped chromatin highly suspicious for chronic lymphocytic leukemia. I know this isn't a dr site but is it time to visit him again?

Hi all, I was intrigued by this article: Case Report of Unexpectedly Long Survival of Patient With Chronic Lymphocytic Leukemia: Why Integrative Methods Matter https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380985/ Has anyone explored this?

I was looking for information regarding cholesterol medication "ezetimibe" and I came across this article. There seams to be a relation between regulating lipid accumulation and CLL. I am currently not taking ezetimibe but I do plan to have a conversation with my doctor to see if we should consider

We've had a few other posts recently regarding the TME; [i] • [/i]Targeting the tumor microenvironment for treating double refractory chronic leukemia posted by newyork917 https://healthunlocked.com/cllsupport/posts/private/150923620/targeting-the-tumor-microenvironment-for-treating-double-refractory-chronic-lymphocytic-leukemia

Ohio State Univeristy, FYI- REMISSION- 8 PLUS YEARS OUT https://www.patientpower.info/chronic-lymphocytic-leukemia/the-lowest-levels-of-cll-ive-ever-seen?

leukemia/small lymphocytic lymphoma (A-CLL/SLL) is a histologically aggressive subtype of CLL/SLL that lies in between conventional CLL/SLL (C-CLL/SLL) and Richter transformation (RT) on the biological spectrum.

leukemia?

The first one was done in June 2022): HEMATOPATHOLOGY CONSULTATION Date Ordered: 11/7/2024 INTERPRETATION FINAL DIAGNOSIS: PERIPHERAL BLOOD: - CHRONIC LYMPHOCYTIC LEUKEMIA IMMUNOLOGIC CHARACTERIZATION BY FLOW CYTOMETRY, PERIPHERAL BLOOD: - KAPPA (WEAK) MONOTYPIC B LYMPHOID CELL POPULATION

I was diagnosed in February with CCL Chronic lymphocytic leukemia. It was discovered because of kidney problems. I’m having treatment for that and everything is going well according to my hematologist. I made the tests in February regarding bence jones, lambda and everything returned negative.

Wierda, MD Anderson https://www.patientpower.info/chronic-lymphocytic-leukemia/asco-2024-your-cll-update

Lower cholesterol concentrations were reported in patients with chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) than in healthy controls (108, 109), but a different report documented high cholesterol levels in patients with CLL (110).

"Amoxicillin should be used with caution in patients with lymphocytic leukemia who are more susceptible to rashes (maculopapular skin reactions). Do you know anything? What other antibiotic could I substitute it for?

A recent article. 27 Dec 2024 Somewhat surprising findings, but the trend in SLL inclusion in CLL clinical trials is improving. I suspect some of this is driven by the need to have active disease in the peripheral blood at adequate levels for trial participation. https://onlinelibrary.wiley.com/doi

leukemia (CLL) who had previously received a covalent Bruton's tyrosine kinase (BTK) inhibitor, a phase III study showed.

with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?